How accurately can MRI detect indolent disease?

Area of Science:

• Urology
• Radiology
• Oncology

Background:

• Accurate prostate cancer diagnosis is challenged by the need to differentiate aggressive tumors requiring intervention from indolent disease suitable for active surveillance.
• Standard 12-core systematic biopsies can misclassify tumor volume or grade in up to 30% of cases, impacting treatment decisions.
• Integrating magnetic resonance imaging (MRI) into the diagnostic pathway offers potential for improved risk stratification.

Purpose of the Study:

• To evaluate the role of multiparametric MRI in identifying patients with very low-risk prostate cancer.
• To assess the potential of MRI to refine treatment decisions between active intervention and active surveillance.
• To determine if MRI can better identify clinically insignificant prostate cancer.

Main Methods:

• Review of recent advances in prostate imaging techniques, focusing on multiparametric MRI.
• Analysis of the negative predictive value of multiparametric MRI in ruling out clinically significant prostate cancer.
• Consideration of prospective studies to evaluate MRI-targeted biopsy in patients eligible for active surveillance.

Main Results:

• Multiparametric MRI demonstrates a high negative predictive value (up to 95%) for excluding clinically significant prostate cancer.
• MRI shows potential clinical utility in diagnostic pathways for men at risk of prostate cancer.
• Nonsuspicious multiparametric MRI findings identify a distinct low-risk patient group.

Conclusions:

• Patients with unremarkable multiparametric MRI results represent a very low-risk cohort, potentially having no disease or clinically insignificant disease.
• Conservative management is a viable option for men with nonsuspicious multiparametric MRI findings.
• Further prospective studies are needed to confirm the utility of MRI-targeted biopsy for active surveillance eligibility.